Protein / target
Carbapenem-hydrolyzing beta-lactamase KPC-2
Protein at a glance
Biological role
Beta-lactamase
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Class A beta-lactamase which confers resistance to the beta-lactam antibiotics, including penicillins, cephalosporins and carbapenems.
View complete UniProt function annotationHide complete annotation
Class A beta-lactamase which confers resistance to the beta-lactam antibiotics, including penicillins, cephalosporins and carbapenems (PubMed:11257029). Acts via hydrolysis of the beta-lactam ring (PubMed:11257029, PubMed:33257320). Has penicillin-, cephalosporin- and carbapenem-hydrolyzing activities (PubMed:11257029, PubMed:33257320)
Domains and Gene Ontology detail (4)Hide
Gene Ontology
- Ccytosol
- Fbeta-lactamase activity
- Pbeta-lactam antibiotic catabolic process
- Presponse to antibiotic
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Carbepenem-hydrolyzing beta-lactamase KPC inhibitor
Indicated for Urinary Tract Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.